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CASE PRESENTATION
A 24-year-old man presented with hemoptysis. Chest
radiographs revealed a right upper lobe mass. Positron
emission tomography-computed tomography confirmed a
7.4-cm hypermetabolic right upper lobe mass. The patient
underwent right upper lobectomy, which demonstrated a
7.7-cm pulmonary blastoma. Surgical margins and 3 N1
lymph nodes were negative. Adjuvant chemotherapy was
recommended but was declined by the patient. Five years
later, he again presented with significant hemoptysis.
Chest computed tomography scan demonstrated an 8.9-cm
right lung mass, which abutted the mediastinum (Figure 1).
Positron emission tomography-computed tomography con-
firmed localized disease. The tumor was deemed unresect-
able. Biopsy to confirm disease recurrence was not per-
formed because he was having significant hemoptysis, and
the clinical picture was consistent with recurrent pulmo-
nary blastoma. The original treatment plan was for defin-
itive radiation therapy to a dose of 60 Gy with concurrent
cisplatin and etoposide. However, his tumor regressed
substantially after 2 weeks of therapy. Therefore, a preop-
erative course of radiation therapy and chemotherapy was
pursued. The tumor was treated to a total dose of 50 Gy in
2 Gy daily fractions. He received two cycles of cisplatin
(50 mg/m2 on days 1 and 8) and etoposide (50 mg/m2 on
days 1–5) during weeks 1 and 5 of radiotherapy.
The patient tolerated treatment exceptionally well,
developing grade 2 acute esophagitis, which was managed
with viscous lidocaine. Three weeks after completing pre-
operative therapy, a chest computed tomography was re-
peated showing dramatic regression of disease (Figure 2).
The patient subsequently underwent surgical resection, which
required a completion right pneumonectomy. Pathology re-
vealed a 6.3-cm pulmonary blastoma with significant scarring
and pleural fibrosis. His original pathology was reviewed
and found to be identical. Surgical margins were negative,
and there was no evidence of regional lymph node involve-
ment. Two additional cycles of chemotherapy were rec-
ommended, which he is currently receiving.
DISCUSSION
Pulmonary blastoma is an uncommon malignancy
occurring principally in adults. In the World Health Orga-
nization classification, pulmonary blastoma is included
under the category of carcinomas with pleomorphic, sar-
comatoid, or sarcomatous elements.1 The World Health
Organization differentiates pulmonary blastoma from
pleuropulmonary blastoma, which are soft tissue tumors
arising from the lung parenchyma and pleura in children.
Pleuropulmonary blastoma can be distinguished both his-
tologically and clinically from pulmonary blastoma.1,2
There is no clear consensus as to what combination of
therapy is optimal for pulmonary blastoma. Nevertheless, most
agree that surgical resection should be performed if possible.3
The role of adjuvant radiation therapy and chemotherapy is not
clear, but given the propensity for recurrence are often admin-
istered. For patients with unresectable disease, there is limited
data on the effectiveness of definitive radiation therapy, with or
without chemotherapy. Isolated case reports suggest that pulmo-
nary blastomas do respond to radiation therapy.4,5
To our knowledge, this is the first report of preop-
erative radiation therapy and chemotherapy followed by
gross total resection for pulmonary blastoma. Our patient
was deemed unresectable at presentation due to the origi-
nal extent of disease with possible invasion of the medi-
astinum. Nevertheless, shortly after initiating combined
modality therapy, the tumor decreased substantially in size
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and became resectable. For patients with pulmonary blas-
toma who initially present with unresectable disease, this
approach should be considered.
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FIGURE 1. Contrast enhanced chest computed tomography demonstrating the extent of tumor recurrence. Representative
axial images with soft tissue windows at the level of the aortic arch (A) and right pulmonary artery (B). The mass is predomi-
nantly homogeneous; however, areas of low attenuation suggestive of necrosis are present. There is thickening of the right
anterior pleura (arrow). Direct chest wall invasion is not readily identified. The central mass compresses and posteriorly dis-
places the right pulmonary artery. The mass extends superiorly to the lung apex and inferiorly to the level of the right lower
pulmonary vein and closely adheres to the right upper lobectomy staple line (black arrowhead). There is loss of normal medi-
astinal fat planes (white arrowhead); however, streak artifact from the superior vena cava limits evaluation. The size of the
mass and apposition to pericardium, central vessels, and other mediastinal structures are highly suggestive of invasion.
FIGURE 2. Noncontrast chest computed to-
mography at the completion of radiation ther-
apy and chemotherapy. Representative axial
images at the level of the aortic arch (A) and
right pulmonary artery (B) demonstrate marked
reduction in tumor size (residual tumor de-
noted by arrow) with resultant clearing of the
mediastinal margins. (Arrowhead denotes prior
post upper lobectomy staple line.) Anterior
pleural involvement has resolved.
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